Study reveals motor neuron region is affected in ALS
The neurological condition currently affects one in 300 people in the UK
Read Moreby Jen Brogan | Dec 6, 2023 | News | 0
The neurological condition currently affects one in 300 people in the UK
Read Moreby Lucy Parsons | Oct 29, 2020 | News | 0
Agreement will also see companies develop treatments for frontotemporal dementia
Read Moreby Selina McKee | Jul 13, 2020 | News | 0
Clinigen has bagged a US orphan drug designation (ODD) for its investigational Amyotrophic Lateral Sclerosis (ALS) treatment aldesleukin.
Read Moreby Selina McKee | Jul 13, 2020 | News | 0
Phase I/II study results demonstrate proof-of-concept and proof-of-biology of tofersen
Read Moreby Selina McKee | Nov 2, 2018 | News | 0
Sanofi is linking with Denali Therapeutics on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases.
Read Moreby Selina McKee | May 23, 2018 | News | 0
Clinigen says it has partnered with Mitsubishi Tanabe Pharma to initiate a Managed Access Program in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (ALS).
Read Moreby Selina McKee | Apr 23, 2018 | News | 0
AB Science’s share price has taken a hit after European Medicine Agency’s advisors rejected approval of masitinib for amyotrophic lateral sclerosis.
Read Moreby Selina McKee | Jan 4, 2018 | News | 0
Pfizer and Sangamo Therapeutics are linking arms to develop a potential gene therapy to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
Read Moreby Selina McKee | Aug 9, 2016 | News | 0
European regulators have assigned orphan drug status to an experimental therapy for Amyotrophic Lateral Sclerosis called masitinib, indicating that it has the potential to offer a significant benefit over existing treatment options.
Read Moreby Selina McKee | Jun 22, 2016 | News | 0
US regulators have agreed to review Mitsubishi Tanabe’s application to market edaravone for the treatment of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurological disease.
Read Moreby Selina McKee | Jun 21, 2016 | News | 0
US regulators have agreed to review Mitsubishi Tanabe’s application to market edaravone for the treatment of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurological disease.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479